CU20220047A7 - 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación - Google Patents
2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparaciónInfo
- Publication number
- CU20220047A7 CU20220047A7 CU2022000047A CU20220047A CU20220047A7 CU 20220047 A7 CU20220047 A7 CU 20220047A7 CU 2022000047 A CU2022000047 A CU 2022000047A CU 20220047 A CU20220047 A CU 20220047A CU 20220047 A7 CU20220047 A7 CU 20220047A7
- Authority
- CU
- Cuba
- Prior art keywords
- quinazolin
- piperazin
- trifluoromethyl
- fluoro
- methoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>La presente invención se refiere a Ia nueva 3,4-dihidroquinazolina, 2-[(4<em>S</em>)-8-fluoro-2-[4-(3-metoxifeniI)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)feniI]-4<em>H</em>-quinazolin-4-il] acetato de sodio monohidrato de fórmula I</p> <p>Fórmula I</p> <p>métodos para su preparación, así como composiciones farmacéuticas que contienen dicha 3,4-dihidroquinazolina. Dicho compuesto es particularmente útil para el tratamiento y prevención de enfermedades asociadas con citomegalovirus (CMV), particularmente citomegalovirus humano (HCMV).<br /> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159709 | 2020-02-27 | ||
| PCT/EP2021/055065 WO2021170879A1 (en) | 2020-02-27 | 2021-03-01 | Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate monohydrate, its preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20220047A7 true CU20220047A7 (es) | 2023-04-10 |
Family
ID=69742712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2022000047A CU20220047A7 (es) | 2020-02-27 | 2021-03-01 | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230219900A1 (es) |
| EP (1) | EP4110469A1 (es) |
| JP (1) | JP7579350B2 (es) |
| KR (1) | KR20220147655A (es) |
| CN (1) | CN115427111A (es) |
| AR (1) | AR121440A1 (es) |
| AU (1) | AU2021225364B2 (es) |
| BR (1) | BR112022016906A2 (es) |
| CA (1) | CA3169473A1 (es) |
| CL (1) | CL2022002290A1 (es) |
| CO (1) | CO2022012017A2 (es) |
| CU (1) | CU20220047A7 (es) |
| EC (1) | ECSP22066670A (es) |
| IL (1) | IL295633A (es) |
| MX (1) | MX2022010440A (es) |
| MY (1) | MY210486A (es) |
| PE (1) | PE20230347A1 (es) |
| PY (1) | PY2116987A (es) |
| TW (1) | TWI886221B (es) |
| UY (1) | UY39098A (es) |
| WO (1) | WO2021170879A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119731157A (zh) * | 2022-08-15 | 2025-03-28 | 上海迪赛诺化学制药有限公司 | 一种来特莫韦无定形的制备方法 |
| PY24113872A (es) | 2023-12-21 | 2025-07-29 | Aic 246 Ag & Co Kg | Sales diastereoméricas de aminoalchohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica.- |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE102005027517A1 (de) | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
-
2021
- 2021-02-26 AR ARP210100498A patent/AR121440A1/es unknown
- 2021-02-26 PY PY202102116987A patent/PY2116987A/es unknown
- 2021-02-26 UY UY0001039098A patent/UY39098A/es unknown
- 2021-03-01 US US17/802,815 patent/US20230219900A1/en active Pending
- 2021-03-01 WO PCT/EP2021/055065 patent/WO2021170879A1/en not_active Ceased
- 2021-03-01 JP JP2022551563A patent/JP7579350B2/ja active Active
- 2021-03-01 MY MYPI2022004571A patent/MY210486A/en unknown
- 2021-03-01 EP EP21708009.2A patent/EP4110469A1/en active Pending
- 2021-03-01 CN CN202180014856.2A patent/CN115427111A/zh active Pending
- 2021-03-01 CA CA3169473A patent/CA3169473A1/en active Pending
- 2021-03-01 MX MX2022010440A patent/MX2022010440A/es unknown
- 2021-03-01 KR KR1020227033584A patent/KR20220147655A/ko not_active Ceased
- 2021-03-01 CU CU2022000047A patent/CU20220047A7/es unknown
- 2021-03-01 PE PE2022001802A patent/PE20230347A1/es unknown
- 2021-03-01 BR BR112022016906A patent/BR112022016906A2/pt unknown
- 2021-03-01 IL IL295633A patent/IL295633A/en unknown
- 2021-03-01 AU AU2021225364A patent/AU2021225364B2/en active Active
- 2021-03-02 TW TW110107369A patent/TWI886221B/zh active
-
2022
- 2022-08-22 CL CL2022002290A patent/CL2022002290A1/es unknown
- 2022-08-23 CO CONC2022/0012017A patent/CO2022012017A2/es unknown
- 2022-08-24 EC ECSENADI202266670A patent/ECSP22066670A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202140454A (zh) | 2021-11-01 |
| CL2022002290A1 (es) | 2023-02-03 |
| MX2022010440A (es) | 2022-10-18 |
| TWI886221B (zh) | 2025-06-11 |
| PY2116987A (es) | 2021-12-01 |
| JP7579350B2 (ja) | 2024-11-07 |
| KR20220147655A (ko) | 2022-11-03 |
| US20230219900A1 (en) | 2023-07-13 |
| JP2023519809A (ja) | 2023-05-15 |
| AU2021225364A1 (en) | 2022-10-13 |
| CN115427111A (zh) | 2022-12-02 |
| CO2022012017A2 (es) | 2022-11-18 |
| AR121440A1 (es) | 2022-06-08 |
| UY39098A (es) | 2021-09-30 |
| ECSP22066670A (es) | 2022-12-30 |
| AU2021225364B2 (en) | 2024-11-28 |
| WO2021170879A1 (en) | 2021-09-02 |
| BR112022016906A2 (pt) | 2022-12-06 |
| IL295633A (en) | 2022-10-01 |
| NZ792571A (en) | 2025-07-25 |
| PE20230347A1 (es) | 2023-03-02 |
| EP4110469A1 (en) | 2023-01-04 |
| CA3169473A1 (en) | 2021-09-02 |
| MY210486A (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ594741A (en) | Specific diarylhydantoin and diarylthiohydantoin compounds | |
| PE20050965A1 (es) | Procedimiento para la preparacion de compuestos de aminocrotonilo | |
| PE20080359A1 (es) | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r | |
| MX2010005997A (es) | Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales. | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| PE131699A1 (es) | Inhibidores de aminotiazol de cinasas dependientes de ciclina | |
| MX358961B (es) | Compuestos de tetraciclina sustituidos con fluor en c7. | |
| PE20140966A1 (es) | Quinazolincarboxamida azetidinas | |
| PE20081704A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
| CU20220047A7 (es) | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación | |
| NO20062905L (no) | Nye hydroksaminsyreestere og farmasoytisk anvendelse derav | |
| ATE540932T1 (de) | Hydantoin-derivate als antibakterielle wirkstoffe | |
| US11040963B2 (en) | Piperazine derivatives for influenza virus inhibitions | |
| PE20080364A1 (es) | Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa | |
| NZ607580A (en) | N-heteroaryl compounds | |
| WO2011025982A3 (en) | Tetracycline compounds | |
| PE20141201A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
| PE20142083A1 (es) | Derivados de anilina, su preparacion y su aplicacion terapeutica | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| HRP20090439T1 (hr) | Supstituirani derivati propenil piperazina kao novi inhibitori histonske deacetilaze | |
| WO2018141854A1 (en) | Piperazine derivatives for influenza virus inhibition | |
| MX2024008172A (es) | Procedimiento para la preparación del ácido (5s)-{[2-(4-carboxifenil)etil][2- (2-{[3-cloro-4'-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]amino}-5,6,7,8- tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo | |
| AR076516A1 (es) | Derivados de oxa-azaespiro[3.3]heptan-6-ilo, metodo e intermediarios para su preparacion, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor mch1. | |
| Braker et al. | Substituted Sulfanilamidopyrimidines1 |